Victory Capital Management’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Victory Capital Management’s Portfolio ARDS Stock Details ARDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,068	Closed	-$12K	–	3482
2020 Q1	$12K	Buy	+2,068	New	+$13.2K	﹤0.01%	3268
2019 Q4	–	Sell	-934	Closed	-$6K	–	3469
2019 Q3	$6K	Buy	+934	New	+$8.55K	﹤0.01%	3428

Other funds holding ARDS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Financial Perspectives Minneapolis, Minnesota $411M AUM 26.27% 1-Year Est. Return

Victory Capital Management's ARDS Position: Q2 2020 in Review

Victory Capital Management sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q2 2020, closing a stake of 2,068 shares — an estimated $12K sold.

Victory Capital Management first reported a position in ARDS in Q3 2019 and held it in 2 quarters. The position peaked at $12K in Q1 2020. 8 funds tracked by Wall St. Rank hold ARDS as of Q2 2020.

Victory Capital Management reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Victory Capital Management sold 2,068 Aridis Pharmaceuticals Inc. Common Stock shares in Q2 2020, an estimated $12K.
Victory Capital Management first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q3 2019 and held it in 2 quarters.
Victory Capital Management's Aridis Pharmaceuticals Inc. Common Stock position peaked at $12K in Q1 2020.
8 funds tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.